Cargando…

Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma

Glioblastoma (GB) is the most common and devastating form of brain cancer. Despite conventional treatments, progression or recurrences are systematic. In recent years, immunotherapies have emerged as an effective treatment in a number of cancers, leaving the question of their usefulness also faced w...

Descripción completa

Detalles Bibliográficos
Autores principales: Grégoire, Hélène, Roncali, Loris, Rousseau, Audrey, Chérel, Michel, Delneste, Yves, Jeannin, Pascale, Hindré, François, Garcion, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158850/
https://www.ncbi.nlm.nih.gov/pubmed/32322199
http://dx.doi.org/10.3389/fphar.2020.00368
_version_ 1783522569424470016
author Grégoire, Hélène
Roncali, Loris
Rousseau, Audrey
Chérel, Michel
Delneste, Yves
Jeannin, Pascale
Hindré, François
Garcion, Emmanuel
author_facet Grégoire, Hélène
Roncali, Loris
Rousseau, Audrey
Chérel, Michel
Delneste, Yves
Jeannin, Pascale
Hindré, François
Garcion, Emmanuel
author_sort Grégoire, Hélène
collection PubMed
description Glioblastoma (GB) is the most common and devastating form of brain cancer. Despite conventional treatments, progression or recurrences are systematic. In recent years, immunotherapies have emerged as an effective treatment in a number of cancers, leaving the question of their usefulness also faced with the particular case of brain tumors. The challenge here is major not only because the brain is the seat of our consciousness but also because of its isolation by the blood-brain barrier and the presence of a unique microenvironment that constitutes the central nervous system (CNS) with very specific constituent or patrolling cells. Much of the microenvironment is made up of immune cells or inflammation. Among these, tumor-associated macrophages (TAMs) are of significant interest as they are often involved in facilitating tumor progression as well as the development of resistance to standard therapies. In this review, the ubiquity of TAMs in GB will be discussed while the specific case of microglia resident in the brain will be also emphasized. In addition, the roles of TAMs as accomplices in the progression of GB and resistance to treatment will be presented. Finally, clinical trials targeting TAMs as a means of treating cancer will be discussed.
format Online
Article
Text
id pubmed-7158850
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71588502020-04-22 Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma Grégoire, Hélène Roncali, Loris Rousseau, Audrey Chérel, Michel Delneste, Yves Jeannin, Pascale Hindré, François Garcion, Emmanuel Front Pharmacol Pharmacology Glioblastoma (GB) is the most common and devastating form of brain cancer. Despite conventional treatments, progression or recurrences are systematic. In recent years, immunotherapies have emerged as an effective treatment in a number of cancers, leaving the question of their usefulness also faced with the particular case of brain tumors. The challenge here is major not only because the brain is the seat of our consciousness but also because of its isolation by the blood-brain barrier and the presence of a unique microenvironment that constitutes the central nervous system (CNS) with very specific constituent or patrolling cells. Much of the microenvironment is made up of immune cells or inflammation. Among these, tumor-associated macrophages (TAMs) are of significant interest as they are often involved in facilitating tumor progression as well as the development of resistance to standard therapies. In this review, the ubiquity of TAMs in GB will be discussed while the specific case of microglia resident in the brain will be also emphasized. In addition, the roles of TAMs as accomplices in the progression of GB and resistance to treatment will be presented. Finally, clinical trials targeting TAMs as a means of treating cancer will be discussed. Frontiers Media S.A. 2020-04-08 /pmc/articles/PMC7158850/ /pubmed/32322199 http://dx.doi.org/10.3389/fphar.2020.00368 Text en Copyright © 2020 Grégoire, Roncali, Rousseau, Chérel, Delneste, Jeannin, Hindré and Garcion http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Grégoire, Hélène
Roncali, Loris
Rousseau, Audrey
Chérel, Michel
Delneste, Yves
Jeannin, Pascale
Hindré, François
Garcion, Emmanuel
Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
title Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
title_full Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
title_fullStr Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
title_full_unstemmed Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
title_short Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
title_sort targeting tumor associated macrophages to overcome conventional treatment resistance in glioblastoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158850/
https://www.ncbi.nlm.nih.gov/pubmed/32322199
http://dx.doi.org/10.3389/fphar.2020.00368
work_keys_str_mv AT gregoirehelene targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma
AT roncaliloris targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma
AT rousseauaudrey targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma
AT cherelmichel targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma
AT delnesteyves targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma
AT jeanninpascale targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma
AT hindrefrancois targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma
AT garcionemmanuel targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma